Philippe Moreau, MDEnriched profile
Professor of Clinical Hematology, Nantes Faculty of Medicine (appointed 2003); Head of the Hematology Department, University Hospital of Nantes (CHU de Nantes); President, International Myeloma Society · Centre National de la Recherche Scientifique
Overview
Updated 14 Jul 2026
Philippe Moreau is Professor of Clinical Hematology, Nantes Faculty of Medicine (appointed 2003) at CHU de Nantes (Nantes University Hospital) / Nantes Université Faculty of Medicine. The public record shows 2,103 publications with 103,109 citations (h-index 153), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology. It also documents an investigator role on 8 registered clinical trials.
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Multiple Myeloma Research and Treatments
- 8 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 77 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 877.
Clinical & industrytrials, payments and federal funding
Not shown. No U.S. clinical registration on file.
Federally funded research awards.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- MInimal Residual Disease Adapted Strategy
Sponsor: Intergroupe Francophone du Myelome
InvestigatorPhase 3Active, not recruitingNCT04934475 - A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Sponsor: Intergroupe Francophone du Myelome
InvestigatorPhase 3CompletedNCT02541383 - Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
Sponsor: Nantes University Hospital
InvestigatorPhase 3CompletedNCT01971658
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited worksby citation count (OpenAlex)
- 01
- 02Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma2,435 citations2021
- 03
- 04Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma1,434 citations2016
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
CHU de Nantes, Hôtel-Dieu, 5 allée de l'Île-Gloriette, 44093 Nantes Cedex 01, France
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- Appointed University Professor (Professeur des Universités) of Clinical Hematology
Nantes Faculty of Medicine
2003verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →chu-nantes.fr ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →chu-nantes.fr ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →themmrf.org ↗
- President
International Myeloma Society (IMS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
Awards & honorshonors on the public record
- Robert A. Kyle Lifetime Achievement Award
International Myeloma Foundation (2018), awarded at the IMF's 9th Annual Summit in Stockholm (June 12, 2018) for outstanding contributions to multiple myeloma research …
2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →chu-nantes.fr ↗
Secondary affiliationsappointments beyond the home institution
- Scientific Advisory Board member
Multiple Myeloma Research Foundation (MMRF)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →themmrf.org ↗ - Scientific advisor
ONK Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onktherapeutics.com ↗ - Team member
SIRIC ILIAD Nantes Angers (Integrated Cancer Research Site)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →siric-iliad.com ↗
Media & interviewspress, podcasts and appearances
- HealthTree for Multiple Myeloma podcast: "The Future of Bispecific Antibodies with Dr. Moreau" (Feb 2025)
page confirms head of Hematology Dept, University Hospital of Nantes and President of IMS
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗ - OncLive video/text interview series (multiple appearances)
e.g. "Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/nantes-universite_talent-un-nantais-parmi-les-chercheurs-activity-6737710228881711104-KmEN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
healthtree.org/myeloma/community/directory/international/university-hospital-of-nantes/philippe-moreau
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗ - Other
myelomasociety.org/officers/philippe-moreau-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Boston University
- 3,069
- publications
- 199
- h-index
- 5
- trials
Paul Richardson, MD
Harvard University
- 2,062
- publications
- 172
- h-index
- 17
- trials
S Rajkumar, MD
WinnMed
- 1,861
- publications
- 166
- h-index
- 11
- trials
Meletios Dimopoulos, MD
Korea University
- 2,990
- publications
- 159
- h-index
- 13
- trials